Journal issues > Issue 1, February 2019 > Highlights in chronic myeloid leukemia

Highlights in chronic myeloid leukemia

With respect to chronic myeloid leukemia (CML), the 2018 annual meeting of the American Society of Hematology featured the following sessions: The CML educational session, 3 oral sessions with 6 abstract presentations each, and a long list of posters. This report will briefly summarize the key messages from the educational session discussing the choice of first-line treatment in CML patients. The highlights from the oral and poster sessions will be grouped in three categories: new drugs in CML, treatment-free remission (TFR) and CML and pregnancy.

(BELG J HEMATOL 2019;10(1):31–5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top